Wellgistics Health (WGRX) Targets Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. ALAR
3. SPY
4. PBA
5. CCH:LN
6. META
7. BAJAJHFL:I
8. CCHGY
9. PRY:IM
10. PRYMY

Go back to Wellgistics Health (WGRX) Targets Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet

Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)

March 9, 2026 7:40 AM EDT

GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301

Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary side effect

Forzet targeting preservation of muscle while on GLP-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain

TAMPA, FLORIDA / ACCESS Newswire / March 9, 2026 / Wellgistics Health, Inc. (NASDAQ: WGRX)... More